O BLEeding excess with antiplatelet treatment with thromboserin during coronary artery bypass grafting (CABG)
Completed
- Conditions
- Topic: CardiovascularSubtopic: Cardiovascular (all Subtopics)Disease: CardiovascularCirculatory SystemThrombosis
- Registration Number
- ISRCTN59071456
- Lead Sponsor
- Imperial College London (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 120
Inclusion Criteria
The original protocol, which received ethical and MHRA approval states. All patients requiring cardiac surgery.
Exclusion Criteria
The original protocol, which received ethical and MHRA approval states.
Patients with bradycardia or bradyarrhythmia, unless drug induced and the drug stopped (e.g. ß- adrenoreceptor antagonists).
Patients treated with serotonin re-uptake inhibitors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie thromboserin's antiplatelet effects in CABG-related bleeding management?
How does thromboserin compare to standard anticoagulants like heparin in reducing post-CABG hemorrhagic complications?
Which biomarkers correlate with thromboserin efficacy in patients undergoing coronary artery bypass grafting?
What are the thromboserin-associated adverse events and strategies for mitigating bleeding risks during CABG?
How do thromboserin-based regimens interact with direct oral anticoagulants in cardiovascular surgery trials?